Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
D. Western Therapeutics Institute (FRA:6DW) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
D. Western Therapeutics Institute Pretax Margin % Related Terms
D. Western Therapeutics Institute Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute Pretax Margin % Chart
FRA:6DW vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, D. Western Therapeutics Institute's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute (FRA:6DW) has a Pretax Margin % of % as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on D. Western Therapeutics Institute and its competitors. According to the industry distribution chart, D. Western Therapeutics Institute ranks #582 out of 944 companies in the Biotechnology industry, placing it in the top 61.7%.
Is D. Western Therapeutics Institute's Pretax Margin % too high?
D. Western Therapeutics Institute's current Pretax Margin % is %. Based on the distribution chart, D. Western Therapeutics Institute ranks #582 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, D. Western Therapeutics Institute has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #582 out of 944 companies for Pretax Margin %. This places D. Western Therapeutics Institute in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on D. Western Therapeutics Institute and its competitors. D. Western Therapeutics Institute's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
D. Western Therapeutics Institute (FRA:6DW) has a current Pretax Margin % of %. The stock's GF Value™ is €0.21, compared to a current price of €0.42 — trading 98.1% above its estimated fair value. The current Pretax Margin % is %. D. Western Therapeutics Institute's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For D. Western Therapeutics Institute (FRA:6DW), the current Pretax Margin % is % as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (FRA:6DW) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of €0.42 is trading 98.1% above its estimated GF Value™ of €0.21.
Key valuation signals for FRA:6DW:
Pretax Margin %: %
GF Value™: €0.21 vs. price of €0.42 (98.1% above fair value)
No single metric tells the full story. See the FRA:6DW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
49GF Score
Get the complete analysis for FRA:6DW
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6DW has been successfully added to your 
